Brill, E., Yokoyama, T., Nair, J., Yu, M., Ahn, Y., & Lee, J. (2017). Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer. Oncotarget.
Chicago Stili AlıntıBrill, Ethan, Takuhei Yokoyama, Jayakumar Nair, Minshu Yu, Yeong-Ran Ahn, ve Jung-Min Lee. "Prexasertib, a Cell Cycle Checkpoint Kinases 1 and 2 Inhibitor, Increases in Vitro Toxicity of PARP Inhibition By Preventing Rad51 Foci Formation in BRCA Wild Type High-grade Serous Ovarian Cancer." Oncotarget 2017.
MLA AlıntıBrill, Ethan, et al. "Prexasertib, a Cell Cycle Checkpoint Kinases 1 and 2 Inhibitor, Increases in Vitro Toxicity of PARP Inhibition By Preventing Rad51 Foci Formation in BRCA Wild Type High-grade Serous Ovarian Cancer." Oncotarget 2017.